

### **Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the specification:

#### **Listing of Claims:**

Claim 1 (original): A coprecipitate of amorphous rosiglitazone maleate with a pharmaceutically acceptable carrier.

Claim 2 (original): A coprecipitate of amorphous rosiglitazone maleate with a pharmaceutically acceptable carrier according to claim 1, wherein the carrier is selected from the group consisting of polyvinylpyrrolidone, silicium dioxide, mannitol, lactose, methylcellulose and cyclodextrin.

Claim 3 (original): The coprecipitate according to claim 1, wherein it is the coprecipitate of amorphous rosiglitazone maleate with polyvinylpyrrolidone.

Claim 4 (original): The coprecipitate according to claim 1, wherein it is the coprecipitate of amorphous rosiglitazone maleate with silicon dioxide.

Claim 5 (original): The coprecipitate according to claim 1, wherein it is the coprecipitate of amorphous rosiglitazone maleate with mannitol.

Claim 6 (original): The coprecipitate according to claim 1, wherein it is the coprecipitate of amorphous rosiglitazone maleate with lactose.

Claim 7 (original): The coprecipitate according to claim 1, wherein it is the coprecipitate of amorphous rosiglitazone maleate with methylcellulose.

Claim 8 (original): The coprecipitate according to claim 1, wherein it is the coprecipitate of amorphous rosiglitazone maleate with gamma-cyclodextrin.

Claim 9 (currently amended): A coprecipitate according to claims 1 to 8, wherein the ratio of amorphous rosiglitazone maleate to a pharmaceutically acceptable carrier ranges from 1 : 1 to 1 : 20.

Claim 10 (currently amended): A coprecipitate according to claims 1 to 8, wherein the ratio of amorphous rosiglitazone maleate to a pharmaceutically acceptable carrier ranges from 1 : 1 to 1 : 4.

Claim 11 (original): A process for the preparation of a coprecipitate of amorphous rosiglitazone maleate with a pharmaceutically acceptable carrier, which comprises the steps of:

- a) dissolving rosiglitazone maleate in an organic solvent or in an aqueous solution of organic solvent,
- b) adding pharmaceutically acceptable carrier,
- c) spray-drying the obtained solution.

Claim 12 (original): The process according to claim 11, wherein a pharmaceutically acceptable carrier is selected from the group consisting of polyvinylpyrrolidone, silicon dioxide, mannitol, lactose, methylcellulose and cyclodextrin.

Claim 13 (original): The process according to claim 11, wherein an organic solvent is selected from the group consisting of ethanol and acetone.

Claim 14 (original): The process according to claim 11, wherein the range of organic solvent to water is from about 9 : 1 to about 1 : 1 (V / V).

Claim 15 (original): The process according to claims 11, wherein the range of organic solvent to water is from about 9 : 1 to about 7 : 3 ( V / V )

Claim 16 (original): A process for the preparation of a coprecipitate of amorphous rosiglitazone maleate with a pharmaceutically acceptable carrier, which comprises the steps of:

- d) dissolving rosiglitazone (base) in an organic solvent
- e) adding maleic acid and stirred the mixture to obtain a clear solution,
- f) adding pharmaceutically acceptable carrier,
- g) spray-drying the obtained solution.

Claim 17 (cancelled).

Claim 18 (currently amended): A coprecipitate of amorphous rosiglitazone maleate with a pharmaceutically acceptable carrier according to claims 1 to 10, for use in the treatment and / or

prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.

Claim 19 (cancelled).

Claim 20 (original): A solid solution of rosiglitazone maleate with a pharmaceutically acceptable carrier.

Claim 21 (currently amended): A solid solution according to claim 20, wherein the pharmaceutically acceptable carrier is selected from polyethylene glycols between 4000 to ~~40.000~~ 40,000 of average mol. weight.

Claim 22 (original): A process for the preparation of a solid solution of rosiglitazone maleate with a pharmaceuticall acceptable carrier, which comprises the steps of:

- h) melting rosiglitazone maleate or optionally rosiglitazone and maleic acid with a pharmaceutically acceptable carrier to form a melt
- i) cooling the obtained melted solution

Claims 23-24 (cancelled).